BIOMED-LUBLIN WYT.SUR.

Research BIOMED-LUBLIN WYT.SUR. (6NQ) on Bullrun: market cap EUR 46.90M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker6NQ
• ExchangeF
• CountryPoland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 46.90M
• Financial periodQ3 2025
• RevenueEUR 4.79M
• Net income-EUR 7.73M
• Free cash flow-EUR 18.79M
• Gross margin34.8%

Valuation Snapshot

latest market cap is EUR 46.90M.

About BIOMED-LUBLIN WYT.SUR.

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors;

Frequently asked questions

What is BIOMED-LUBLIN WYT.SUR.'s market cap?

BIOMED-LUBLIN WYT.SUR.'s market capitalization is EUR 46.90M.

What does BIOMED-LUBLIN WYT.SUR. do?

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments.